In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases
- PMID: 19528274
- PMCID: PMC2715587
- DOI: 10.1128/AAC.00641-09
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases
References
-
- Bassetti, M., E. Righi, and C. Viscoli. 2008. Novel β-lactam antibiotics and inhibitor combinations. Expert Opin. Investig. Drugs 17:285-296. - PubMed
-
- Bonnefoy, A., C. Dupuis-Hamelin, V. Steier, C. Delachaume, C. Seys, T. Stachyra, M. Fairley, M. Guitton, and M. Lampilas. 2004. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. 54:410-417. - PubMed
-
- Bratu, S., P. Tolaney, U. Karumudi, J. Quale, M. Mooty, S. Nichani, and D. Landman. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128-132. - PubMed
-
- CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 7th ed. CLSI M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
-
- CLSI. 2009. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical